Candidate for MSCA IF 2017 at ITACA. Universitat Politècnica de València (UPV)

Brief description of the institution:

Universitat Politècnica de València (UPV) is the single Spanish Technical University that features in the main University world rankings. It is within the top 5 Spanish Universities with the highest revenue from both public research and knowledge transfer activities, and a national leader in patent license income and start up creation. Constituted in 1971, it comprises nearly 30.000 students, over 2500 academics, and 17 university research centres of excellence. 

UPV has a relevant experience in the participation in international research programmes, with over 100 FP7 projects and 60 H2020 projects in the period 2014-2016. UPV researchers are also actively involved in all H2020 life program stages, from workprogramme drafting discussions, to project coordination. It is also taking part in several major partnering initiatives (JTIs, PPPs, KICs…).

Brief description of the Centre/Research Group (including URL if applicable):

The mission of ITACA is the applied research in the Information and Communication Technologies (ICT) field and especially on biomedical applications. ITACA focuses its effort to the development of research and technologies for public and private companies, both in the national and the international scope. By the development of those technological innovations, ITACA aims to reinforce the competitiveness and economic development of the industrial sector, which are directly reflected to the European Society.

Project description:

Cardiac Regeneration Medicine

Chronic heart failure (HF) is a worldwide epidemic and the most common cause of mortality and morbidity worldwide, and its prevalence continues to increase. In spite of new therapies, cardiac remodelling and subsequent HF remain critical issues after myocardial infarction (MI). Cardiac regenerative therapies have the potential to revolutionize the treatment of HF by retarding and even reverting the remodelling process. During the last two decades, preclinical and clinical studies have demonstrated the potential of these techniques. However, the lack of knowledge about their mechanisms of action limits the full potential of those innovative therapies. Members of RESCURE consortium have already significantly contributed to the clarification of the mechanisms of action of cardiac regenerative cell therapies. Now, we plan to optimize and evaluate a novel cardiac regenerative product that we have already produced: decellularized cardiac patches subsequently recellularized with a combination of mesenchymal and cardiac resident stem cells. The aim of the proposal is to validate the efficacy and the mechanisms of action of this innovative regenerative therapy (i.e. MSC/CSC recellularized patches) by means of a translational research approach (i.e. porcine model of HF due to MI).

Applications

Letter of motivation and CV - (No deadline)

http://www.eshorizonte2020.es/expressions-of-interests/andreu-climent